Oryzon develops small molecule inhibitors for epigenetic targets. The two lead drugs are vafidemstat for CNS indications and iadademstat for oncology (both are LSD1 inhibitors, an epigenetic target). In CNS, vafidemstat is being evaluated in two Phase IIb trials, PORTICO in borderline personality disorder, which has shown encouraging interim results to date with top-line data expected in Q124, and EVOLUTION in schizophrenia. Oryzon is also hoping to register vafidemstat in its Phase I/II HOPE study targeting Kabuki syndrome by end-2023. In oncology, positive top-line data have been reported from the ALICE trial in acute myeloid leukaemia (AML) while new trials FRIDA in AML (first patient dosed in Q123) and STELLAR in SCLC could potentially be pivotal, with the FDA having now granted orphan drug designation for iadademstat in AML and SCLC. The FRIDA study represents one of Oryzon’s key strategic priorities.